Roivant Sciences Ltd
F:87S

Watchlist Manager
Roivant Sciences Ltd Logo
Roivant Sciences Ltd
F:87S
Watchlist
Price: 11.29 EUR -0.35% Market Closed
Market Cap: 8.3B EUR
Have any thoughts about
Roivant Sciences Ltd?
Write Note

Roivant Sciences Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Roivant Sciences Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Roivant Sciences Ltd
F:87S
Pre-Tax Income
$4.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Pre-Tax Income
-$176.1m
CAGR 3-Years
-155%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Pre-Tax Income
-$208.4m
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Pre-Tax Income
-$169.6m
CAGR 3-Years
-36%
CAGR 5-Years
-38%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Pre-Tax Income
-ÂŁ60.9m
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Pre-Tax Income
ÂŁ5.5m
CAGR 3-Years
-54%
CAGR 5-Years
-11%
CAGR 10-Years
-18%
No Stocks Found

Roivant Sciences Ltd
Glance View

Market Cap
8.3B EUR
Industry
Biotechnology

Roivant Sciences Ltd. is a dynamic biopharmaceutical company that has carved a unique niche in the pharmaceutical landscape by focusing on the efficient development of innovative therapies. Founded in 2014, Roivant operates on a model that leverages technology and data to accelerate drug discovery and commercialization, which allows it to bring treatments to market more swiftly than traditional pharmaceutical firms. With a roster of subsidiary companies, each specializing in different therapeutic areas, Roivant aims to tackle unmet medical needs, particularly in neuroscience, immunology, and rare diseases. This approach not only diversifies its portfolio but also enhances the potential for successful product launches, appealing to investors looking for promising biotech opportunities. At the heart of Roivant's strategy is its commitment to harnessing innovative technologies, including artificial intelligence and decentralized clinical trials, that streamline the drug development process. The company has established partnerships with leading research institutions and pharmaceutical giants, enhancing its credibility and expanding its reach. As Roivant progresses through clinical trials and advances its pipeline, investors are provided with unique opportunities to participate in groundbreaking treatments that could improve patient outcomes and generate significant returns. With its nimble structure, emphasis on collaboration, and pursuit of disruptive innovations, Roivant stands out as a compelling player in the evolving world of biopharmaceuticals, representing both promise and potential for those willing to engage with its journey.

87S Intrinsic Value
5.17 EUR
Overvaluation 54%
Intrinsic Value
Price

See Also

What is Roivant Sciences Ltd's Pre-Tax Income?
Pre-Tax Income
4.3B USD

Based on the financial report for Mar 31, 2024, Roivant Sciences Ltd's Pre-Tax Income amounts to 4.3B USD.

Back to Top